FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

仅供研究使用。 完整免责声明 →

研究/Exploring the Metabolic Pathways of Alexamorelin: Challenges in Detecting Its Use
返回研究图书馆
AlexamorelinExamorelinHexarelin

Exploring the Metabolic Pathways of Alexamorelin: Challenges in Detecting Its Use

May 16, 2026
Share

原始论文

Identification of alexamorelin consumption biomarkers using human hepatocyte incubations and high-resolution mass spectrometry.

Pobee Elizabeth et al.Journal of analytical toxicology2025
新兴研究

基于新兴研究。这些发现很有前景,但需要进一步验证。

关于此分析

本文将上述源论文的研究成果分解成肽类研究社区易于理解的语言。我们的目标是突出最值得关注的内容 — 实用意义、证据强度以及对正在进行的研究的影响。

Unraveling Alexamorelin's Metabolic Pathways: New Insights but Challenges Persist

Published: May 16, 2026 | Source: Journal of analytical toxicology (2025) | Category: Alexamorelin, Examorelin, Hexarelin

Overview

A recent study published in the Journal of Analytical Toxicology has shed light on the metabolic pathways of alexamorelin, a synthetic peptide with growth hormone secretagogue properties. The research highlights the complexity of detecting this substance's use due to its rapid metabolism and transformation into other peptides like examorelin (hexarelin), which complicates efforts in doping control.

Study Background

Alexamorelin is a performance-enhancing drug that mimics natural hormones to boost growth hormone levels, making it a target for anti-doping regulations. However, identifying biomarkers of its consumption has been challenging due to the rapid and extensive metabolism by the liver. This study aimed to predict and characterize these metabolic pathways using computational tools and in vitro human hepatocyte models.

What the Research Found

The research team used GLORYx software to predict 21 potential metabolites of alexamorelin, with N-acetylation at either the C-terminal alanine or N-terminal lysine being the most likely transformation. After incubating alexamorelin with pooled human hepatocytes for three hours, only one specific metabolite was detected: examorelin (hexarelin), which results from cleavage of the C-terminal alanine residue.

What This Means for Peptide Users

The findings suggest that detecting alexamorelin's use may be more challenging than previously thought due to its rapid transformation into other peptides. Examorelin, a known growth hormone secretagogue, is not specific to alexamorelin consumption, complicating efforts in identifying the exact substance used by athletes or patients.

Limitations and Caveats

The study’s reliance on computational predictions and in vitro hepatocyte models limits its applicability to real-world scenarios involving human subjects. Additionally, the detection of examorelin rather than unique metabolites specific to alexamorelin poses significant challenges for doping control measures.

How This Compares to Previous Research

Previous studies have focused on identifying biomarkers through urine or blood samples from athletes and patients, but this study’s approach provides a more detailed understanding of the metabolic pathways involved. However, it also highlights the need for further research using human subjects to validate these findings in practical settings.

Our Analysis

PeptideVault's analysis suggests that while this study advances our knowledge of alexamorelin metabolism, its limitations underscore the complexity of detecting such substances accurately. The identification of examorelin as a primary metabolite raises questions about the specificity and reliability of current detection methods for performance-enhancing peptides like alexamorelin.

Key Takeaways

  • Complex Metabolism: Alexamorelin undergoes rapid metabolism, primarily through N-acetylation.
  • Challenges in Detection: The transformation into examorelin complicates efforts to detect alexamorelin specifically.
  • Need for Further Research: Studies using human subjects are necessary to validate these findings and improve detection methods.

Original Source

Citation: Pobee Elizabeth, Daziani Gloria, Gameli Prince S et al. (2025). Identification of alexamorelin consumption biomarkers using human hepatocyte incubations and high-resolution mass spectrometry.. Journal of analytical toxicology. DOI: 10.1093/jat/bkaf038

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

编辑注释

此分析由Peptide Contacts研究团队准备。鼓励读者查阅 完整源论文 以获取完整方法和数据。 原始出版物可在 PubMed.

相关研究

Comments

Sign in to join the discussion

此分析基于同行评审研究仅用于教育目的。并不构成医疗建议。在使用任何肽类疗法之前,请咨询合格的医疗服务提供者。